Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Mirvetuximab soravtansine (ovarian cancer) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-06
Last updated

Report documents

  1. Extract of dossier assessment

    Mirvetuximab soravtansine (ovarian cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 851 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-06_en
    Download file : Extract of dossier assessment (PDF document, 851 kB, EN, not accessible)

  2. Dossier assessment

    Mirvetuximab soravtansine (ovarian cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-06
    Download file : Dossier assessment (PDF document, 2 MB, DE, not accessible)

Drug assessment at a glance

  1. Drug assessment at a glance

    Mirvetuximab soravtansine (ovarian cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 386 kB, EN, not accessible
    Download file : Drug assessment at a glance (PDF document, 386 kB, EN, not accessible)

Dossier assessment

Indication:

Adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian cancer who have received 1 to 3 prior systemic treatment regimens

Result of dossier assessment:
  • Patients for whom monotherapy with paclitaxel, PLD or topotecan is a suitable therapy: indication of a major added benefit
  • Patients for whom combination therapy with bevacizumab is a suitable therapy: added benefit not proven

Project details

Project no.
A26-06
Commission
Commission awarded on 28.01.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-06_en

Connected Projects

  1. Dossier assessment

    Mirvetuximab soravtansin (ovarian cancer) – Assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V

    Project no.
    G24-36
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page